Cormorant Asset Management as of Sept. 30, 2017
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 51 positions in its portfolio as reported in the September 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Myokardia | 8.1 | $46M | 1.1M | 42.85 | |
| Ignyta | 7.6 | $43M | 3.5M | 12.35 | |
| Omeros Corporation (OMER) | 6.5 | $37M | 1.7M | 21.62 | |
| Anaptysbio Inc Common (ANAB) | 6.2 | $35M | 1.0M | 34.95 | |
| Theravance Biopharma (TBPH) | 5.7 | $33M | 950k | 34.24 | |
| Portola Pharmaceuticals | 4.8 | $27M | 500k | 54.03 | |
| G1 Therapeutics | 3.9 | $22M | 898k | 24.89 | |
| Bluebird Bio (BLUE) | 3.3 | $19M | 138k | 137.35 | |
| Quotient | 3.0 | $17M | 3.5M | 4.93 | |
| Clearside Biomedical (CLSD) | 3.0 | $17M | 1.9M | 8.74 | |
| Juno Therapeutics | 3.0 | $17M | 375k | 44.86 | |
| Omeros | 2.9 | $16M | 750k | 21.62 | |
| Neurocrine Biosciences (NBIX) | 2.7 | $15M | 250k | 61.28 | |
| Aclaris Therapeutics (ACRS) | 2.5 | $14M | 550k | 25.81 | |
| Reata Pharmaceuticals Inc Cl A | 2.1 | $12M | 389k | 31.10 | |
| Eagle Pharmaceuticals (EGRX) | 2.1 | $12M | 200k | 59.64 | |
| Mirati Therapeutics | 2.1 | $12M | 1.0M | 11.70 | |
| Array BioPharma | 1.9 | $11M | 900k | 12.30 | |
| Alder Biopharmaceuticals | 1.9 | $11M | 900k | 12.25 | |
| Heron Therapeutics (HRTX) | 1.6 | $9.2M | 570k | 16.15 | |
| Nevro (NVRO) | 1.6 | $9.1M | 100k | 90.88 | |
| Audentes Therapeutics | 1.6 | $9.1M | 324k | 28.01 | |
| Zai Lab (ZLAB) | 1.6 | $9.0M | 333k | 27.00 | |
| Protagonist Therapeutics (PTGX) | 1.6 | $8.8M | 500k | 17.67 | |
| Proteostasis Therapeutics In | 1.4 | $8.0M | 3.8M | 2.10 | |
| Gemphire Therapeutics | 1.3 | $7.6M | 800k | 9.44 | |
| Intec Pharma | 1.3 | $7.2M | 810k | 8.95 | |
| Abeona Therapeutics | 1.2 | $6.8M | 400k | 17.05 | |
| Sangamo Biosciences (SGMO) | 1.1 | $6.0M | 400k | 15.00 | |
| Jounce Therapeutics | 1.0 | $5.6M | 360k | 15.58 | |
| Agile Therapeutics | 1.0 | $5.6M | 1.3M | 4.46 | |
| Blueprint Medicines (BPMC) | 0.9 | $5.2M | 75k | 69.67 | |
| Advanced Accelerat spon ads each rep 2 ord | 0.9 | $5.1M | 75k | 67.63 | |
| Mersana Therapeutics (MRSN) | 0.9 | $5.1M | 296k | 17.29 | |
| Minerva Neurosciences | 0.8 | $4.6M | 608k | 7.60 | |
| Wave Life Sciences (WVE) | 0.8 | $4.4M | 202k | 21.75 | |
| Syros Pharmaceuticals | 0.8 | $4.4M | 296k | 14.72 | |
| Cymabay Therapeutics | 0.7 | $4.0M | 500k | 8.06 | |
| Contrafect | 0.7 | $3.9M | 3.6M | 1.11 | |
| Ardelyx (ARDX) | 0.6 | $3.2M | 573k | 5.60 | |
| Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 0.6 | $3.1M | 300k | 10.49 | |
| Trillium Therapeutics, Inc. Cmn | 0.6 | $3.1M | 600k | 5.15 | |
| Immune Design | 0.5 | $2.9M | 281k | 10.35 | |
| Acceleron Pharma | 0.5 | $2.8M | 75k | 37.32 | |
| Ovid Therapeutics (OVID) | 0.3 | $1.9M | 224k | 8.57 | |
| Cytomx Therapeutics (CTMX) | 0.3 | $1.8M | 100k | 18.17 | |
| Curis | 0.3 | $1.7M | 1.2M | 1.49 | |
| Oncobiologics | 0.1 | $814k | 594k | 1.37 | |
| Oncobiologics Inc *w exp 02/18/201 | 0.0 | $50k | 417k | 0.12 | |
| Cellectar Biosciences Equity Warrants *w | 0.0 | $7.9k | 53k | 0.15 | |
| Oncobiologics Inc *w exp 05/18/201 | 0.0 | $21k | 417k | 0.05 |
